Bedrijfsoverzicht
Inogen, Inc. is a medical technology firm dedicated to the development, manufacturing, and marketing of respiratory health products for the United States and international markets, specifically focusing on portable oxygen concentrators that deliver supplemental long-term oxygen therapy to patients with chronic respiratory conditions. The company operates within the Healthcare sector and the Medical Devices industry, a domain characterized by rigorous regulatory standards and specialized demand for life-support equipment. Inogen currently maintains a market capitalization of $172.38M and employs a workforce of 753 individuals across its operational footprint. The company generated total revenue of $348.67M in the trailing twelve months, figures that place it within the mid-cap range of the medical device sector. This specific market capitalization suggests a company that is established enough to have significant production capabilities yet remains smaller than the largest industry peers, indicating a position where it must carefully balance scaling operations against maintaining profitability in a competitive landscape.
Financiële gezondheid
Inogen reported total revenue of $348.67M over the trailing twelve months, yet the company recorded a net income loss of $22,747,000 and an EBITDA of $-9,548,000 during the same period. The substantial gap between the reported revenue of $348.67M and the net income loss reveals a cost structure where operating expenses, including research and development and general administration, significantly exceed gross profits before reaching the bottom line. The company generated negative free cash flow of $-21,157,376, which indicates that capital expenditures and working capital requirements currently outpace operating cash generation, limiting immediate financial flexibility for large-scale acquisitions or aggressive dividend payments. Despite these operational losses, the balance sheet retains $119.58M in cash against total debt of $17.48M, suggesting a conservative liquidity position with ample cash reserves relative to obligations. The debt-to-equity ratio stands at 9.09, a figure that mathematically represents the relationship between liabilities and equity, while the current ratio of 3.12 indicates strong short-term liquidity as the company holds more than three times the current value of its short-term liabilities in assets. Return on Equity is recorded at -12.4% and Return on Assets at -6.3%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or utilized in asset base over the trailing twelve months.
Waarderingsbeoordeling
The valuation metrics for Inogen present a complex picture, with a trailing P/E ratio listed as N/A due to the recent net losses, while the forward P/E is calculated at -20.42. The absence of a positive trailing P/E implies that the market is currently pricing the stock based on future earnings expectations rather than past performance, whereas the negative forward P/E suggests analysts anticipate a path to profitability that has not yet been realized in the current fiscal cycle. The price-to-book ratio is 0.90, indicating that the market values the company at 90% of its book value, which suggests the stock is trading at a discount to its net asset value rather than a premium. Alternative valuation multiples provide further context, with a price-to-sales ratio of 0.49 and an EV/EBITDA of -7.36, suggesting that investors are valuing the firm primarily on revenue generation rather than current earnings power. The stock price has fluctuated between a 52-week high of $9.13 and a 52-week low of $5.34, and based on the forward P/E context, the current trading price sits within this historical range, reflecting market uncertainty regarding the timeline to consistent profitability. The company exhibits a beta of 1.71, a figure that quantifies its price volatility as significantly higher than the broader market, implying that the stock will experience amplified price movements relative to the S&P 500 during periods of market turbulence.
Growth & Income
Inogen demonstrated a revenue growth rate of 2.0% year-over-year, while the earnings growth rate is listed as N/A due to the company's recent net losses. Since earnings are currently negative, they are technically not growing in a profitable sense, but the positive revenue growth indicates that top-line sales are expanding faster than the costs associated with generating that revenue. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning that the firm reinvests all available earnings and cash flow back into the business for research, development, and operational scaling rather than distributing income to shareholders. This reinvestment strategy is typical for medical device companies in the growth or expansion phase that prioritize funding innovation and market penetration over providing immediate income returns. The overall growth and income profile for Inogen is characterized by steady revenue expansion in a critical healthcare sector but is currently offset by the lack of profitability and the absence of dividend distributions to investors.